Linked Life Data

17906297

Source:http://linkedlifedata.com/resource/pubmed/id/17906297

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2008-2-4
pubmed:abstractText
Protein kinase C beta (PKCbeta), a pivotal enzyme in B-cell signaling and survival, is overexpressed in most cases of mantle cell lymphoma (MCL). Activation of PI3K/AKT pathway is involved in pathogenesis of MCL. Enzastaurin, an oral serine/threonine kinase inhibitor, suppresses signaling through PKCbeta/PI3K/AKT pathways, induces apoptosis, reduces proliferation, and suppresses tumor-induced angiogenesis.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Feb
pubmed:issn
1569-8041
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
19
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
247-53
pubmed:dateRevised
2010-11-18
pubmed:meshHeading
pubmed-meshheading:17906297-Administration, Oral, pubmed-meshheading:17906297-Aged, pubmed-meshheading:17906297-Aged, 80 and over, pubmed-meshheading:17906297-Disease-Free Survival, pubmed-meshheading:17906297-Dose-Response Relationship, Drug, pubmed-meshheading:17906297-Drug Administration Schedule, pubmed-meshheading:17906297-Drug Resistance, Neoplasm, pubmed-meshheading:17906297-Female, pubmed-meshheading:17906297-Humans, pubmed-meshheading:17906297-Indoles, pubmed-meshheading:17906297-Kaplan-Meier Estimate, pubmed-meshheading:17906297-Lymphoma, Mantle-Cell, pubmed-meshheading:17906297-Male, pubmed-meshheading:17906297-Maximum Tolerated Dose, pubmed-meshheading:17906297-Middle Aged, pubmed-meshheading:17906297-Prognosis, pubmed-meshheading:17906297-Protein Kinase C, pubmed-meshheading:17906297-Protein Kinase Inhibitors, pubmed-meshheading:17906297-Recurrence, pubmed-meshheading:17906297-Survival Analysis, pubmed-meshheading:17906297-Treatment Outcome
pubmed:year
2008
pubmed:articleTitle
A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma.
pubmed:affiliation
Hematology, Hopital C. Huriez Centre Hospitalier Universitaire, Lille, France. f-morschhauser@chru-lille.fr
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't, Clinical Trial, Phase II